Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors

Biological Psychiatry

Volumn 60, Issue 12, 2006, Pages 1350-1355

  Papakostas, George I ^a   Nutt, David J ^b   Hallett, Lindsay A ^a   Tucker, Vivian L ^c   Krishen, Alok ^c   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

bupropion; fatigue; MDD; Sleepiness; SSRIs; treatment

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; EXPERIENCE; FATIGUE; HAMILTON SCALE; HUMAN; HYPERSOMNIA; MAJOR DEPRESSION; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DISORDERS OF EXCESSIVE SOMNOLENCE; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL FATIGUE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TERMINOLOGY;

EID: 33751546642     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.06.015     Document Type: Article

References (43)

1. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 56 (1995) 395-401
2. Baker M., Dorzab J., Winokur G., and Cadoret R.J. Depressive disease: Classification and clinical characteristics. Compr Psychiatry 12 (1971) 354-365
3. Bonferroni CE (1935): Il calcolo delle assicurazioni su gruppi di teste. In: Studi in Onore del Professore Salvatore Ortu Carboni. Rome, Italy, 13-60.
4. Bonferroni C.E. Teoria statistica delle classi e calcolo delle probabilità. Pubblicazioni del Istituto Superiore di Scienze Economiche e Commerciali di Firenze 8 (1936) 3-62
5. Burke W.J., Gergel I., and Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63 (2002) 331-336
6. Clayton A.H., Croft H.A., Horrigan J.P., Wightman D.S., Krishen A., Richard N.E., and Modell J.G. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 double-blind, placebo-controlled trials. J Clin Psychiatry 67 (2006) 736-746
7. Coleman C.C., Cunningham L.A., Foster V.J., Batey S.R., Donahue R.M., Houser T.L., and Ascher J.A. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11 (1999) 205-215
8. Coleman C.C., King B.R., Bolden-Watson C., Book M.J., Segraves R.T., Richard N., et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23 (2001) 1040-1058
9. Croft H., Settle Jr. E., Houser T., Batey S.R., Donahue R.M., and Ascher J.A. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21 (1999) 643-658
10. Demyttenaire K., De Fruyt J., and Stahl S.M. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 8 (2005) 93-105
11. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry 64 suppl 14 (2003) 30-34
12. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 65 suppl 16 (2004) 27-32
13. Fava M., and Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19 (1996) 179-200
14. Fava M., Rush A.J., Thase M.E., Clayton A., Stahl S.M., Pradko J.F., and Johnston J.A. 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 7 (2005) 106-113
15. Feighner J.P., Gardner E.A., Johnston J.A., Batey S.R., Khayrallah M.A., Ascher J.A., and Lineberry C.G. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52 (1991) 329-335
16. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., and Demitrack M.A. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24 (2004) 389-399
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
18. Horwath E., Johnson J., Weissman M.M., and Hornig C.D. The validity of major depression with atypical features based on a community study. J Affect Disord 26 (1992) 117-125
19. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) guidelines. Available at: http://www.ich.org. Accessed: August 15, 2005.
20. Joliat M., Brown E.B., and Miner C.M. Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine. J Clin Psychopharmacol 24 (2004) 464-467
21. Kavoussi R.J., Segraves R.T., Hughes A.R., Ascher J.A., and Johnston J.A. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58 (1997) 532-537
22. Kennedy S.H., Fulton K.A., Bagby R.M., Greene a., Cohen N.L., and Rafi-Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 51 (2006) 234-242
23. Lepola U.M., Loft H., and Reines E.H. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18 (2003) 211-217
24. Maurice-Tison S., Verdoux H., Gay B., Perez P., Salamon R., and Bourgeois M.L. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 48 (1998) 1245-1246
25. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20 (2005) 131-137
26. Moos R.H., and Cronkite R.C. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis 187 (1999) 360-368
27. Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington III J.J., et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60 (1999) 221-225
28. Papakostas G.I., and Fava M. Monoamine-based Pharmacotherapy. In: Licinio J. (Ed). Biology of Depression: From Novel Insights to Therapeutic Strategies. 1st ed. (2005), Wiley-VCH Verlag, Weinheim 87-140
29. Papakostas G.I., Petersen T., Denninger J.W., Tossani E., Pava J.A., Alpert J.E., et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 24 (2004) 507-511
30. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: An important outcome in depression. Psychol Med 25 (1995) 1171-1180
31. Petersen T., Dording C., Neault N.B., Kornbluh R., Alpert J.E., Nierenberg A.A., et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 177-187
32. Petersen T., Papakostas G.I., Posternak M.A., Kant A., Guyker W.M., Iosifescu D.V., et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 25 (2005) 336-341
33. Posternak M.A., and Zimmerman M. Symptoms of atypical depression. Psychiatry Res 104 (2001) 175-181
34. Rush A.J., Batey S.R., Donahue R.M., Ascher J.A., Carmody T.J., and Metz A. Does pretreatment anxiety predict response to either bupropion SR or sertraline?. J Affect Disord 64 (2001) 81-87
35. Rush A.J., Trivedi M.H., Carmody T.J., Donahue R.M.J., Houser T.L., Bolden-Watson C., et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacol 25 (2001) 131-138
36. Simon G.E., Revicki D., Heiligenstein J., Grothaus L., VonKorff M., Katon W.J., and Hylan T.R. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22 (2000) 153-162
37. Stahl S.M., Zhang L., Dematarca C., and Grady M. Brain circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 64 suppl 14 (2003) 6-17
38. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66 (2005) 974-981
39. Trivedi M.H., Rush A.J., Carmody T.J., Donahue R.M., Bolden-Watson C., Houser T.L., and Metz A. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. J Clin Psychiatry 62 (2001) 776-781
40. Tylee A., Gastpar M., Lepine J.P., and Mendlewicz J. DEPRES II (Depression Research in European Society II): A patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14 (1999) 139-151
41. Weihs K.L., Settle Jr. E.C., Batey S.R., Houser T.L., Donahue R.M., and Ascher J.A. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61 (2000) 196-202
42. Winokur A., Baker R.A., Simmons J., Jansen W.I., and Schutte A. Comparative sleep improving effects of mirtazapine vs SSRIs in depressed patients: A meta-analysis of individual patient data. 8th World Congress of the World Federation of Societies of Biological Psychiatry. Vienna, Austria. World J Biol Psychiatry S1 (2005) 366-367
43. Worthington J., Fava M., Davidson K., Alpert J., Nierenberg A.A., and Rosenbaum J.F. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull 31 (1995) 223-236